Evaluating long-term patient-centered outcomes following prostate cancer treatment: Findings from the Michigan Prostate Cancer Survivor study

Journal of Cancer Survivorship

Volumn 8, Issue 1, 2014, Pages 121-130

  Darwish Yassine, May ^a   Berenji, Manijeh ^b   Wing, Diane ^a   Copeland, Glenn ^c   Demers, Raymond Y ^d   Garlinghouse, Carol ^a   Fagerlin, Angela ^e   Newth, Gail E ^e   Northouse, Laurel ^e   Holmes Rovner, Margaret ^f   Rovner, David ^f   Sims, Jerry ^g   Wei, John T ^b  

^a Michigan Public Health Institute   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MICHIGAN DEPARTMENT OF COMMUNITY HEALTH   (United States)

^d Great Lakes Cancer Institute   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g Prostate Cancer Coalition of Michigan   (United States)

Author keywords

Active surveillance; Cancer; Care gaps; Oncology; Primary care; Prostate; Survivorship; Symptom management; Symptoms; Treatment

Indexed keywords

ADENOCARCINOMA; AFTERCARE; AGED; ARTICLE; HEALTH SERVICE; HEALTH STATUS; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATIENT EDUCATION; PATIENT SATISFACTION; PROSTATE TUMOR; PSYCHOLOGY; QUALITY OF LIFE; SOCIOECONOMICS; STATISTICS; SURVIVOR; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADENOCARCINOMA; AFTERCARE; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DATA COLLECTION; HEALTH SERVICES NEEDS AND DEMAND; HEALTH STATUS; HUMANS; MALE; MICHIGAN; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; PROSTATIC NEOPLASMS; PSYCHOLOGY; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; SURVIVORS; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84897581911     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-013-0312-8     Document Type: Article

References (38)

1. Surveillance, Epidemiology, and End Results (SEER) Program. limited-use data (1973-2006), National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; released April 2009, based on the November 2007 submission. www. seer. cancer. gov. Accessed 23 Nov 2009.
2. American Cancer Society. Prostate cancer overview: what is prostate cancer? www. cancer. org/Cancer/ProstateCancer/OverviewGuide/prostate-cancer-overview-key-statistics. Accessed 11 July 2011.
3. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2): 117-28.
4. Surveillance, Epidemiology, and End Results (SEER) Program. Research data (1973-2008), Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; released April 2011, based on the November 2010 submission. www. seer. cancer. gov. Accessed 7 June 2011.
5. Deimling GT, Bowman KF, Sterns S, Wagner LJ, Kahana B. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology. 2006;15(4): 306-20.
6. Aziz NM, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol. 2003;13(3): 248-66.
7. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18): 1358-67.
8. Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: prostate carcinoma patients' perspectives after prostatectomy or radiation therapy. Cancer. 1997;79(10): 1977-86.
9. Litwin MS. Health-related quality of life after treatment for localized prostate cancer. Cancer. 1995;75 Suppl 7: 2000-3.
10. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273(2): 129-35.
11. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol. 2005;23(12): 2772-80.
12. Dobs A, Darkes MJM. Incidence and management of gynecomastia in men treated for prostate cancer. J Urol. 2005;174(5): 1737-42.
13. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the prostate cancer outcomes study. J Clin Oncol. 2001;19(17): 3750-7.
14. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167(6): 2361-7.
15. Boxer RS, Kenny AM, Dowsett R, Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. The Aging Male. 2005;8(3-4): 207-12.
16. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9): 4261-7.
17. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy or prostate cancer. J Urol. 2000;163(1): 181-6.
18. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004;64(6): 1182-6.
19. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2): 154-64.
20. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24): 3979-83.
21. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90(5): 2618-23.
22. Dockey F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond). 2003;104(2): 195-201.
23. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27): 4448-56.
24. Leaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5): 1036-41.
25. Satariano WA, Ragland KE, van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83(6): 1180-8.
26. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91(12): 2238-45.
27. Poon SA, Silberstein JL, Savage C, Maschino AC, Lowrance WT, Sandhu JS. Surgical practice patterns for male urinary incontinence: analysis of case logs from certifying American urologists. J Urol. 2012;188(1): 205-10.
28. Faucheron JL, Chodez M, Boillot B. Neuromodulation for fecal and urinary incontinence: functional results in 57 consecutive patients from a single institution. Dis Colon Rectum. 2012;55(12): 1278-83.
29. Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med. 2013;10 Suppl 1: 102-11.
30. Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK. The economic burden of prostate cancer survivorship. J Urol. 2010;184(2): 532-8.
31. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6): 899-905.
32. Grunkemeier MN, Vollmer RT. Predicting prostate biopsy results: the importance of PSA, age, and race. Am J Clin Pathol. 2006;126(1): 110-2.
33. American Cancer Society. Survivorship: during and after treatment: survivorship care plans. www. cancer. org/Treatment/SurvivorshipDuringandAfterTreatment/SurvivorshipCarePlans/index. Accessed 7 Jun 2011.
34. Bober SL, Recklitis CJ, Campbell EG, Park ER, Kutner JS, Najita JS, et al. Caring for cancer survivors: a survey of primary care physicians. Cancer. 2009;115 Suppl 18: 4409-18.
35. Skolarus TA, Holmes-Rovner M, Northouse LL, Fagerlin A, Garlinghouse C, Demers RY, et al. Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol. 2013;31(6): 727-32.
36. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20(2): 557-66.
37. Smith T, Stein KD, Mehta CC, Kaw C, Kepner JL, Buskirk T, et al. The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors. Cancer. 2007;109(1): 1-12.
38. Michigan Cancer Consortium. MCC prostate cancer resources. www. michigancancer. org/CancerPlan/ProstateCancer_Resources. cfm. Accessed 7 Jun 2011.